

## Synthetic Studies on Coenzyme Q<sub>10</sub>

Part 3<sup>1)</sup>

### An Improved C<sub>5</sub> + C<sub>45</sub> Approach to the Stereoselective Synthesis of Coenzyme Q<sub>10</sub> via Metal–Halogen Exchange Strategy

by Xiong-Jie Yu, Hui-Fang Dai, and Fen-Er Chen\*

Department of Chemistry, Fudan University, Shanghai, 200433, P. R. China  
(fax: +86 21 65643809; e-mail: rfchen@fudan.edu.cn)

---

An efficient and stereoselective approach to the synthesis of coenzyme Q<sub>10</sub> is described (*Scheme*). The MeOCH<sub>2</sub>-protected *p*-hydroquinone **4** containing the C<sub>5</sub> (*E*)-allyl (*tert*-butyl)dimethylsilyl ether moiety was obtained *via* a halogen–lithium exchange of the MeOCH<sub>2</sub>-protected 2-bromo-5,6-dimethoxy-3-methylhydroquinone **2** and subsequent addition to (*E*)-(t-BuMe<sub>2</sub>Si)-OCH<sub>2</sub>C(Me)=CHCH<sub>2</sub>Br (**3**). The reductive desulfonylation of compound **8**, obtained from **4** *via* **5–7**, was successfully carried out by employing Li/EtNH<sub>2</sub>.

---


**Introduction.** – During recent work on coenzyme Q<sub>10</sub> (**1**) [1], we developed two new stereoselective synthetic routes for this vitamin by coupling of the MeOCH<sub>2</sub>-protected *p*-hydroquinone **6** bearing a C<sub>5</sub>-allyl moiety of (*E*)-configuration and the polyprenyl sulfone by *Masaki*'s protocol [1]. The more attractive point of the above methods is that solanesol, a C<sub>45</sub>-(*all-E*)-polyprenyl alcohol that is readily obtained by extraction from the leaves of tobacco or potato, can be directly utilized in the synthesis of **1**. However, their industrial application is still hampered by the lack of an efficient method for the preparation of compound **6**. In connection with our continued interest in the development of a practical synthetic process for **1**, we now report an efficient and improved synthesis of coenzyme Q<sub>10</sub> (**1**) starting from the MeOCH<sub>2</sub>-protected 2-bromo-5,6-dimethoxy-3-methylhydroquinone **2** and {[(*E*)-4-bromo-2-methylbut-2-enyl]oxy}(*tert*-butyl)dimethylsilane (**3**). The metal–halogen exchange (MHE) applied to **2** followed by the addition of **3** assembled the two parts into the key intermediate **6** needed to complete the synthesis of **1**.

**Results and Discussion.** – The synthesis of coenzyme Q<sub>10</sub> was carried out as depicted in the *Scheme*. The known bromide **2** was obtained in an overall yield of 61% from 2,3-dimethoxy-5-methylcyclohexa-2,5-diene-1,4-dione by using the synthetic methodology reported by *Sato* and co-workers [2]. The (*E*)-allyl bromide **3** was readily prepared from 1-hydroxypropan-2-one in 65% overall yield by the procedure developed by *Eberl* and co-workers [3]. The aryllithium intermediate generated from **2** with BuLi in THF at –78° was then allowed to react with the (*E*)-allyl bromide **3** to afford the allyl silyl

---

<sup>1)</sup> For Parts 1 and 2, see [1].

ether **4** in 68% yield with high stereoselectivity (*(E/Z)* 99:1, GC/MS). The C=C configuration in **4** was unambiguously established by NOESY experiments (see *Fig.*). The  $t\text{-BuMe}_2\text{Si}$  group in **4** was removed by reaction with  $\text{Bu}_4\text{NF}$  in THF at  $0^\circ$ . The resulting alcohol **5** was then transformed to the corresponding (*E*)-allyl chloride **6** upon treatment with 2,6-dimethylpyridine, LiCl, and MsCl in DMF at  $-5^\circ$ , in 96% isolated yield over two steps. Thus, the preparation of the key intermediate **6** was achieved in 65% yield from **2**.



*a*) 1. BuLi, N<sub>2</sub>,  $-78^\circ$ , 20 min; 2. (*E*)-( $t\text{-BuMe}_2\text{Si}$ )-OCH<sub>2</sub>C(Me)=CHCH<sub>2</sub>Br (**3**),  $-78^\circ \rightarrow \text{r.t.}$ , 2 h, r.t., 5 h; 68%. *b*)  $\text{Bu}_4\text{NF}$ , THF,  $0^\circ$ , 40 min. *c*) LiCl, 2,6-dimethylpyridine, DMF, MsCl,  $-5^\circ$ , 4 h; 96% over two steps. *d*) Sodium 4-chlorobenzenesulfonate, DMF, r.t., 24 h; 85%. *e*) 1. BuLi, THF/hexamethylphosphoric triamide (HMPA) 8:1, N<sub>2</sub>,  $-70^\circ$ , 30 min; 2. **6**,  $-70^\circ \rightarrow \text{r.t.}$ , 2 h, r.t., 1 h; 75%. *f*) 1. EtNH<sub>2</sub>, Li, THF,  $-78^\circ$ , 30 min; 2. isoprene, solid NH<sub>4</sub>Cl, 86%. *g*) HCl (cat.), MeOH/hexane 2:1,  $40^\circ$ , 3 h; 93%.




Figure. NOESY Correlation for compound 4

Solanesyl bromide [4], prepared from solanesol, (= (2*E*,6*E*,10*E*,14*E*,18*E*,22*E*,26*E*,30*E*)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-ol) was treated with sodium 4-chlorobenzenesulfinate in DMF at room temperature to give solanesyl 4-chlorophenyl sulfone (**7**) in 85% yield [4]. Coupling of the sulfone **7** through its lithium anion in the presence of chloride **6** afforded the intermediate **8** in 75% yield [5]. Removal of the 4-chlorophenylsulfonyl group in **8** was achieved with Li/EtNH<sub>2</sub> in THF at –78° for 30 min, in a similar manner as reported previously [6], to afford the desired product **9** in 86% yield after chromatographic purification. Analysis of the <sup>1</sup>H-NMR spectrum and HPLC of the crude product **9** indicated that C=C bond migration from C(6)=C(7) to C(5)=C(6) of the side chain during the desulfonation took place to an extent of only 4%. Deprotection of **9** with conc. HCl in hexane and *in situ* oxidation of the resulting hydroquinone by air afforded **1** in 93% yield [1].

**Conclusions.** – In conclusion, a highly efficient synthesis of coenzymeQ<sub>10</sub> (**1**) has been achieved which has the potential to be used for the large-scale production.

#### Experimental Part

*General.* Reagents and chemicals were obtained from commercial suppliers and used without further purification. THF was distilled from sodium/benzophenone. CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, and HMPA were distilled from CaH<sub>2</sub>. Petroleum ether for column chromatography (CC) had a b.p. of 30–60°. HPLC: Shimadzu-LC-10AT liquid chromatograph with Spd-10A UV/VIS detector, working at 270 nm; L<sub>3</sub> column (25 × 4.6 mm); elution with hexane/AcOEt 95:5 at a flow rate 2.0 ml/min. M.p.: WRS-1B digital metal point apparatus. IR Spectra: Jasco-FT/IR-4200 spectrometer. NMR Spectra: Bruker AV 400. Mass Spectra: Waters-Quattro-Micromass spectrometer. GC/MS: Agilent GC/MS spectrometer.

(*tert*-Butyl)[(2*E*)-4-(3,4-dimethoxy-2,5-bis(methoxymethoxy)-6-methylphenyl)-2-methylbut-2-enyl]oxydimethylsilane (**4**). At –78°, 2.89M BuLi in hexane (1.5 ml) was added dropwise to a soln. of **2** (0.751 g, 2.14 mmol) in THF (15 ml) under N<sub>2</sub>. The orange mixture thus obtained was stirred at –78° for additional 20 min. A soln. of **3** (1.19 g, 4.28 mmol) in THF (2.0 ml) was added dropwise, and the resulting mixture was warmed to r.t. within 2 h. After stirring for 5 h at r.t., the mixture was taken up in Et<sub>2</sub>O (3 × 50 ml) and washed with 1N aq. HCl (20 ml), H<sub>2</sub>O (25 ml), and brine (25 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was purified by CC (SiO<sub>2</sub>, petroleum ether/AcOEt 13:1): pure **4** (0.683 g, 67.9%), (*E*)/(*Z*) 99:1 (GC/MS). Colorless oil. IR (film): 2989, 2856, 1471, 1159, 1058, 1027, 837. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 0.02 (s, Me<sub>2</sub>Si); 0.87 (s, <sup>t</sup>BuSi); 1.75 (s, Me–C(2)); 2.17 (s, Me–C(6')); 3.40 (d, <sup>3</sup>J = 6.8, CH<sub>2</sub>(4)); 3.57, 3.58 (2s, 2 MeOCH<sub>3</sub>); 3.85 (2s, MeO–C(3'), MeO–C(4')); 4.0 (s, CH<sub>2</sub>(1)); 5.04 (s, 2 OCH<sub>2</sub>O); 5.32 (t, <sup>3</sup>J = 6.4, H–C(3)). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): –5.3, –5.0 (Me<sub>2</sub>Si); 12.5 (Me–C(6')); 13.6 (Me–C(2)); 18.4 (Me<sub>3</sub>C); 25.7 (CH<sub>2</sub>(4)); 25.9 (Me<sub>3</sub>C); 57.4 (2 MeOCH<sub>3</sub>); 60.9, 60.9 (MeO–C(3'), MeO–C(4')); 68.7 (C(1)); 99.3, 99.5 (2 OCH<sub>2</sub>O); 123.2 (C(6')); 126.0 (C(3)); 129.1 (C(1')); 134.6 (C(2)); 144.4 (C(3')); 144.8 (C(4')); 144.9 (C(5')); 145.3 (C(2')). EI-MS: 470 (7, M<sup>+</sup>), 294 (44), 249 (100), 229 (37), 73 (31). HR-EI-MS: 470.2743 (M<sup>+</sup>, C<sub>24</sub>H<sub>42</sub>O<sub>7</sub>Si<sup>+</sup>; calc. 470.2700).

(2E)-4-(3,4-Dimethoxy-2,5-bis(methoxymethoxy)-6-methylphenyl)-2-methylbut-2-en-1-ol (**5**). Bu<sub>4</sub>NF·H<sub>2</sub>O (0.39 g, 1.5 mmol) in THF (5 ml) was quickly added to a soln. of **4** (0.47 g, 1 mmol) in THF (20 ml) at 0°. After stirring at 0° for 40 min, the reaction was quenched with an sat. aq. NH<sub>4</sub>Cl soln. (15 ml). The aq. phase was extracted with Et<sub>2</sub>O (3 × 15 ml), the combined org. phase washed with brine (4 × 10 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated, and the crude product purified by CC (SiO<sub>2</sub>, petroleum ether/AcOEt 4:1): pure **5** (0.344 g, 96.6%). Colorless oil. IR (film): 3431, 2924, 1467, 1427, 1393, 1158, 1055, 975. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.63 (s, OH); 1.83 (s, Me-C(2)); 2.18 (s, Me-C(6')); 3.42 (d, <sup>3</sup>J = 6.4, CH<sub>2</sub>(4)); 3.58, 3.60 (2s, 2 MeOCH<sub>2</sub>); 3.86 (s, MeO-(3'), MeO-C(4')); 4.00 (s, CH<sub>2</sub>(1)); 5.05, 5.08 (2s, 2 OCH<sub>2</sub>O); 5.35 (t, <sup>3</sup>J = 5.1, H-C(3)). EI-MS: 356 (27, M<sup>+</sup>), 294 (86), 249 (100), 235 (26), 217 (83), 189 (32), 83 (43), 45 (91). HR-EI-MS: 356.1851 (M<sup>+</sup>, C<sub>18</sub>H<sub>28</sub>O<sub>7</sub><sup>+</sup>; calc. 356.1835).

1-[ (2E)-4-Chloro-3-methylbut-2-enyl]-3,4-dimethoxy-2,5-bis(methoxymethoxy)-6-methylbenzene (**6**). MsCl (0.2 ml, 2.63 mmol) was added dropwise to a stirred suspension of **5** (0.36 g, 1.01 mmol), 2,6-dimethylpyridine (0.32 ml, 2.73 mmol) and LiCl (0.107 g, 2.53 mmol) in DMF (20 ml) at -5°. After stirring at -5° for 4 h, H<sub>2</sub>O (30 ml) was added, the resulting mixture extracted with petroleum ether/Et<sub>2</sub>O 1:1 (3 × 40 ml), the combined org. phase washed with H<sub>2</sub>O (4 × 30 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated, and the crude product purified by CC (SiO<sub>2</sub>, petroleum ether/AcOEt 10:1): pure **6** (0.365 g, 96.8%). Colorless oil. IR (film): 2991, 1159, 1103, 1025, 974, 666. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.89 (s, Me-C(3')); 2.17 (s, Me-C(6)); 3.44 (d, <sup>3</sup>J = 6.4, CH<sub>2</sub>(1')); 3.56, 3.59 (2s, 2 MeOCH<sub>2</sub>); 3.85, 3.86 (2s, MeO-C(3), MeO-C(4)); 4.00 (s, ClCH<sub>2</sub>(4')); 5.05, 5.06 (2s, 2 OCH<sub>2</sub>O); 5.48 (t, <sup>3</sup>J = 6.6, H-C(2')). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 12.4 (Me-C(6)); 14.3 (Me-C(3')); 26.2 (CH<sub>2</sub>(1')); 52.2 (C(4')); 57.4 (2 MeOCH<sub>2</sub>); 60.9 (MeO-C(3), MeO-(4)); 99.3, 99.5 (2 OCH<sub>2</sub>O); 125.9 (C(6)); 128.0 (C(2')); 129.1 (C(1)); 131.6 (C(3')); 144.34 (C(3)); 144.9 (C(4)); 145.0 (C(5)); 145.3 (C(2)). EI-MS: 376 (1, M(<sup>37</sup>Cl)<sup>+</sup>), 374 (3, M(<sup>35</sup>Cl)<sup>+</sup>), 294 (44), 249 (100), 217 (38), 91 (14). HR-EI-MS: 376.1452/374.1480 (M<sup>+</sup>, C<sub>18</sub>H<sub>27</sub>ClO<sub>6</sub><sup>+</sup>; calc. 376.1467/374.1496).

1-Chloro-4-[ (2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenylsulfonfyl]benzene (**7**). Sodium 4-chlorobenzenesulfinate (2.98 g, 15 mmol) and solanesyl bromide, prepared from solanesol (6.3 g, 10 mmol) and phosphorous tribromide (0.5 ml, 5 mmol), were dissolved in DMF (80 ml). After stirring for 24 h at r.t., the mixture was poured into H<sub>2</sub>O (50 ml) and Et<sub>2</sub>O (50 ml), the aq. phase extracted with Et<sub>2</sub>O (3 × 80 ml), the combined org. phase washed with H<sub>2</sub>O (3 × 80 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated, and the crude product recrystallized from EtOH: pure **7** (6.7 g, 85%). White solid. M.p. 49.1–49.6°. IR (KBr): 3087, 3053, 2919, 1664, 1582, 1152, 1089, 767. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.36, 1.60, 1.68 (3s, 10 MeC=CH); 1.98–2.10 (m, 8 (CH<sub>2</sub>)<sub>2</sub>C=C); 3.80 (d, <sup>3</sup>J = 7.2, SO<sub>2</sub>CH<sub>2</sub>); 5.05–5.19 (m, 9 C=CH); 7.50 (d, <sup>3</sup>J = 8.8, 2 arom. H); 7.50 (d, <sup>3</sup>J = 8.8, 2 arom. H). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 16.0, 16.3 (8 MeC=C); 17.6 (1 Me-C(35')); 25.6 (1 Me-C(35')); 26.1, 26.6–26.7 (8 CH<sub>2</sub>CH=C); 39.6–39.7 (8 CH<sub>2</sub>C(Me)=C); 56.1 (SO<sub>2</sub>CH<sub>2</sub>(1')); 110.0 (C(2')); 123.1–124.4 (8 CH=C); 129.2–131.1 (8 C(Me)=C); 134.8–135.8 (C(3'), C(2), C(3), C(5), C(6)); 137.2 (C(1)); 145.3 (C(4)); 140.3 (C(1)). ESI-MS: 813.9 (20, [M(<sup>37</sup>Cl) + Na]<sup>+</sup>), 812.9 (24), 811.9 (37, [M(<sup>35</sup>Cl) + Na]<sup>+</sup>) 475.5 (53), 301.3 (100). HR-MALDI-MS: 813.5353 and 811.5385 ([M + Na]<sup>+</sup>, C<sub>51</sub>H<sub>77</sub>ClNaO<sub>2</sub>S<sup>+</sup>; calc. 813.5303 and 811.5333).

1-[ (2E,6E,10E,14E,18E,22E,26E,30E,34E)-5-(4-Chlorophenylsulfonfyl)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-3,4-dimethoxy-2,5-bis(methoxymethoxy)-6-methylbenzene (**8**). At -70°, 2.89M BuLi in hexane (0.5 ml) was added dropwise under stirring to a soln. of **7** (0.95 g, 1.2 mmol) in THF/HMPA 8:1 (25 ml), within 30 min under N<sub>2</sub>. After stirring at -70° for 30 min, a soln. of **6** (0.258 g, 0.69 mmol) in THF (2 ml) was added dropwise, and the resulting mixture was allowed to warm to r.t. over 2 h. After stirring for 1 h at r.t., H<sub>2</sub>O (20 ml) was added, the mixture extracted with Et<sub>2</sub>O (3 × 50 ml), the combined org. phase washed with In aq. HCl (50 ml) and H<sub>2</sub>O (50 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated, and the crude product purified by CC (SiO<sub>2</sub>, petroleum ether/AcOEt 8:1): pure **8** (0.59 g, 75.8%). Yellow oil. IR (film): 3050, 2958, 2922, 1664, 1597, 1056, 978, 665. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.23 (s, MeC=C); 1.60 (s, 8 MeC=C); 1.68, 1.70 (2s, 2 MeC=C); 1.85–2.10 (m, 8 (CH<sub>2</sub>)<sub>2</sub>CH=C, Me-C(6)); 2.22 (t, <sup>2</sup>J = -12.4, <sup>3</sup>J = 12.4, 1 H, CH<sub>2</sub>(4')); 2.88 (d, <sup>2</sup>J = -12.4, 1 H, CH<sub>2</sub>(4')); 3.28 (dd, <sup>2</sup>J = -15.2, <sup>3</sup>J = 6.4, 1 H, CH<sub>2</sub>(1')); 3.35 (dd, <sup>2</sup>J = -15.2, <sup>3</sup>J = 6.4, 1 H, CH<sub>2</sub>(1')); 3.54, 3.57 (2s, 2 MeOCH<sub>2</sub>O); 3.84 (s, MeO-C(3), MeO-C(4)); 3.89 (m, H-C(5')); 4.84 (d, <sup>3</sup>J = 10.4, H-C(6')); 5.00, 5.02 (2s, 2 OCH<sub>2</sub>O); 5.07–5.13 (m, 9 C=CH); 7.46 (d, <sup>3</sup>J = 8.4, 2 arom. H (ArSO<sub>2</sub>)); 7.75

(*d*,  $^3J = 8.4$ , 2 arom. H (ArSO<sub>2</sub>)). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 12.4 (*Me*-C(6)); 16.0, 16.3, 16.6 (9 *MeC*=C); 17.7 (1 *Me*-C(39')); 25.7 (1 *Me*-C(39')); 26.2 (C(1')); 26.3, 26.7–26.8 (8 CH<sub>2</sub>CH=C); 37.4 (C(4')); 39.7–39.8 (8 CH<sub>2</sub>C(*Me*)=C); 57.4 (SO<sub>2</sub>CH); 60.9 (2 *MeOCH*<sub>2</sub>O); 63.7 (*MeO*-C(3), *MeO*-C(4)); 99.4, 99.5 (2 OCH<sub>2</sub>O); 117.0 (C(6)); 122.3 (C(6')); 124.0–124.4, 125.8, 127.0 (9 CH=C); 129.8 (C(1)); 128.7, 129.0, 130.8 (4 CH (ArSO<sub>2</sub>)); 131.2 (C(39')); 134.9–135.2, 135.8 (8 C(*Me*)=C); 136.5 (C(3')); 140.2 (C(ArSO<sub>2</sub>)); 144.4(C(3)); 144.8 (C(4), ClC(ArSO<sub>2</sub>)); 145.3 (C(5)); 145.6 (C(2)). ESI-MS: 1151.4 (3, [M(<sup>37</sup>Cl) + Na]<sup>+</sup>), 1150.4 (3), 1149.4 (4, [M(<sup>35</sup>Cl) + Na]<sup>+</sup>), 411.4 (82), 301.3 (100). HR-MALDI-MS: 1151.6875 and 1149.6907 ([M + Na]<sup>+</sup>, C<sub>69</sub>H<sub>103</sub>ClNaO<sub>8</sub>S<sup>+</sup>; calc. 1151.6930 and 1149.6960).

1-*f*-(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-3,4-dimethoxy-2,5-bis(methoxymethoxy)-6-methylbenzene (**9**). EtNH<sub>2</sub> (ca. 15 ml) was condensed at –78° into a flask containing a soln. of **8** (1.13 g, 1.0 mmol) in THF (5 ml). Small pieces of Li (ca. 70 mg, excess) were added under Ar (→ dark blue). After stirring vigorously at –78° for 30 min, the reaction was quenched with isoprene (0.3 ml). Solid NH<sub>4</sub>Cl was added until the blue color disappeared. The excess metal was removed with forceps, and the mixture was then diluted with Et<sub>2</sub>O (15 ml) and H<sub>2</sub>O (20 ml). The aq. phase was extracted with Et<sub>2</sub>O (2 × 20 ml), the extract dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated, and the crude product purified by CC (SiO<sub>2</sub>, petroleum ether/AcOEt 15:1): pure **9** (0.82 g, 86.1%; > 96% pure by HPLC). White solid. M.p. 27.9–28.6°. IR (KBr): 2923, 2853, 1450, 1428, 1391, 1349, 1159, 1056, 978. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.58, 1.60, 1.68, 1.75 (4s, 11 *MeC*=C); 1.95–2.10 (*m*, 9 (CH<sub>2</sub>)<sub>2</sub>CH=C); 2.17 (*s*, *Me*-C(6)); 3.37 (*d*,  $^3J = 6.4$ , CH<sub>2</sub>(1')); 3.58, 3.60 (2s, 2 *MeOCH*<sub>2</sub>); 3.86 (*s*, *MeO*-C(3), *MeO*-C(4)); 5.04, 5.05 (2s, 2 OCH<sub>2</sub>O); 5.04–5.13 (*m*, 10 C=CH). MALDI-MS: 975.6 ([M + Na]<sup>+</sup>, C<sub>63</sub>H<sub>100</sub>NaO<sub>6</sub><sup>+</sup>).

Coenzyme Q<sub>10</sub> (=2-*f*-(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34-decaenyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; **1**). A soln. of **9** (0.48 g, 0.50 mmol) in MeOH/hexane 2:1 (60 ml) containing one drop of sat. aq. HCl soln. was stirred at 40° for 4 h. After cooling to r.t., the soln. was neutralized with KOH in MeOH to pH 7. H<sub>2</sub>O (10 ml) was added, and the resulting mixture was extracted with hexane (3 × 50 ml). The combined org. phase was washed with H<sub>2</sub>O (3 × 25 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product, which was accompanied by a small amount of isomeric compounds (3.5% by HPLC), was purified by CC (SiO<sub>2</sub>; petroleum ether/AcOEt 15:1): **1** (80.2 mg, 93.0%). Orange oil, which gradually solidified. M.p. 49–49.5° ([16]: m.p. 48–49°). IR (KBr): 2923, 2853, 1655, 1615, 1450, 1385, 1265, 1155. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 1.58, 1.60 (2s, 9 *MeC*=C); 1.68 (*s*, *MeC*=C); 1.74 (*s*, *MeC*=C); 2.01 (*s*, *Me*-C(3)); 1.93–2.09 (*m*, 9 (CH<sub>2</sub>)<sub>2</sub>CH=C); 3.18 (*d*,  $^3J = 6.9$ , CH<sub>2</sub>(1')); 3.98, 4.00 (2s, *MeO*-C(5), *MeO*-C(6)); 4.93 (*t*,  $^3J = 7.3$ , C=CH); 5.04–5.13 (*m*, 9 C=CH). MALDI-MS: 885.7 ([M + Na]<sup>+</sup>, C<sub>59</sub>H<sub>90</sub>NaO<sub>4</sub><sup>+</sup>).

## REFERENCES

- [1] X. J. Yu, F. E. Chen, H. F. Dai, X. X. Chen, Y. Y. Kuang, B. Xie, *Helv. Chim. Acta* **2005**, *88*, 2575; H. F. Dai, F. E. Chen, X. J. Yu, *Helv. Chim. Acta* **2006**, *89*, 1317.
- [2] K. Sato, S. Inoue, R. Yamaguchi, *J. Org. Chem.* **1972**, *37*, 1889.
- [3] A. Eisenführ, P. S. Arora, G. Sengle, L. R. Takaoka, J. S. Nowick, M. Famuloka, *Bioorg. Med. Chem.* **2003**, *11*, 235; M. M. Martínez, D. Hoppe, *Eur. J. Org. Chem.* **2005**, 1427; A. Reichenberg, M. Hintz, Y. Kletschek, T. Kuhl, C. Haug, R. Engel, J. Moll, D. N. Ostrovsky, H. Jomaa, M. Eberl, *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1257.
- [4] K. Sato, O. Miyamoto, S. Inoue, T. Yamamoto, Y. Hirasawa, *J. Chem. Soc., Chem. Commun.* **1982**, 153.
- [5] K. Sato, O. Miyamoto, S. Inoue, Y. Matsuhashi, S. Koyama, T. Kaneko, *J. Chem. Soc., Chem. Commun.* **1986**, 1761.
- [6] E. M. Kaiser, *Synthesis* **1972**, 391; D. S. Dodd, A. C. Oehlschlager, *J. Org. Chem.* **1992**, *57*, 2794.

Received February 13, 2007